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amino acid triplet codons engage different transfer RNAs. These 
enzyme machineries thus allow for diversifi cation of the proteome 
or even correction of the genome code. Although the role of diver-
sifi cation by cytidine-to-uracil (C-to-U) RNA editing in genera-
tion of immunoglobulin variability is under debate (Honjo et al., 
2005) the critical impact of RNA editing on correction of genome 
codes is well established. For example, the permeability of glutamate 
receptors for calcium ions increases when adenosine-to-inosine 
(A-to-I) RNA editing is prohibited, resulting in severe epilepsy 
(Brusa et al., 1995). Therefore in this case, the A-to-I RNA edit-
ing machinery is required for maintenance of physiological brain 
state through correction of unwanted genome codes (Seeburg and 
Hartner, 2003). The number of identifi ed RNA-edited transcripts 
steadily increases, and for example serotonin receptors, potassium 
channels, GABA and glycine receptors were recently included in 
this register (Gurevich et al., 2002; Bhalla et al., 2004; Buckingham 
et al., 2005; Meier et al., 2005).
GlyR C-TO-U RNA EDITING IS NOT SPECIES-SPECIFIC
A cDNA clone corresponding to GlyR α3185L was originally isolated 
from Sprague Dawley rat brain, and molecular analysis revealed the 
involvement of C-to-U RNA editing in proline-to-leucine substitu-
tion at position 185 of the mature GlyR α3 protein (Meier et al., 
2005). Molecular analysis of hippocampi from pharmacoresistant 
temporal lobe epilepsy (TLE) patients further revealed expression 
of mRNAs coding for the high affi nity GlyR α3185L variant (Eichler 
et al., 2008). In addition, GLRA2 transcripts of GlyR α2192L were 
found in these patients. Sequencing of corresponding exons demon-
strated lack of genomic α2192L codons, again supporting the involve-
ment of C-to-U RNA editing in proline-to-leucine substitution in 
GLYCINE RECEPTOR GENES AND SUBUNITS
Glycine receptors (GlyRs) are pentameric chloride (Cl−) channels. 
They contribute to inhibition of neuron fi ring in brain. Expression 
of GlyR genes (GLRA1-4) produces four different α subunits that are 
capable of forming functional, homomeric channels (Betz and Laube, 
2006; Lynch, 2009), while a single gene (GLRB) delivers neurons 
with GlyR β subunit mRNA. Besides modulation of ligand binding 
(Grudzinska et al., 2005) the GlyR β subunit mediates receptor sta-
bilization at postsynaptic sites (Kirsch et al., 1991; Meyer et al., 1995; 
Meier et al., 2000, 2001; Meier and Grantyn, 2004). GlyR genes are 
located on several chromosomes in humans, with GLRA1 on chro-
mosome 5 (5q32), GLRA2 on chromosome X (Xp22.1-p21.3) and 
GLRA3 as well as GLRB on chromosome 4 (4q33-q34 and 4q31.3, 
respectively). GLRA4 is a pseudogene (Simon et al., 2004) located on 
the X-chromosome, position Xq22.2. Expression of all other genes 
occurs in a wide range of brain regions (Lynch, 2009), and generally 
it is thought that GlyR α2 expression predominates in the juvenile 
brain and declines with development (Lynch, 2009). However, at least 
in retina (Haverkamp et al., 2004) and in the hippocampus (Eichler 
et al., 2008) GlyR α2 expression persists throughout development.
FOR WHAT PURPOSE DO WE NEED RNA EDITING?
Through RNA editing the genetically encoded information can 
be modifi ed. Enzymatic deamination of adenosine and cytidine is 
mediated by adenosine deaminases acting on RNA (ADAR) and 
apolipoprotein B mRNA editing complex (APOBEC) or activation 
induced deaminase (AID), respectively (Anant and Davidson, 2001; 
Seeburg and Hartner, 2003; Honjo et al., 2005). The resulting inos-
ine (equivalent to guanosine) or uracil may then lead to amino acid 
substitutions in corresponding proteins, provided that the resulting 
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TLE patients (Eichler et al., 2008). However, the amount of RNA-
edited GLR transcripts was not constant between TLE patients, but 
increased according to the frequency of  secondarily generalized 
tonic-clonic seizures or the degree of hippocampal  sclerosis. That 
hippocampal sclerosis was associated with increased amounts of 
RNA-edited GLRA2/3 transcripts indicates a pathophysiological role 
of high affi nity GlyRs in human hippocampus, which already was 
suggested by our data on experimentally induced brain lesion (Meier 
et al., 2005). Consequently, in TLE patients without hippocampal 
sclerosis the amount of RNA-edited GLR transcripts was very low, 
particularly in case of GlyR α3 (below 1% of GLRA3 transcripts). 
This renders quantifi cation of RNA-edited transcripts rather dif-
fi cult (Nakae et al., 2008). However, our methods for quantifi cation 
were recently shown to be suitable for detection of RNA-edited 
messenger fractions below 1% (Eichler et al., 2008).
LEUCINE AT POSITIONS 192 (α2) AND 185 (α1 AND α3) IS 
RESPONSIBLE FOR HIGH APPARENT GlyR AGONIST AFFINITY
GlyRs are members of the ligand-gated ion channel (LGIC) super-
family, which among others comprises A- and C-type GABA recep-
tors (GABA
A/C
R) and the nicotinic acetylcholine receptor (nAChR). 
All members share common structural features, particularly in the 
ligand binding domain (Celie et al., 2005). In fact, all GlyR subunits 
and GABA
A
R β1-3 contain proline at the position corresponding to 
amino acid 185 of the mature signal-peptide cleaved α3 protein.
However, GABA
A
Rs that require a high agonist affi nity because 
of their involvement in tonic inhibition of neuronal excitability 
don’t have proline at this position. Instead, GABA
A
Rs containing 
α4, α6 or δ subunits are equipped with aliphatic hydrophobic 
neutral amino acids (such as alanine, leucine or valine) (Meier 
et al., 2005), and these receptors are well known to respond to 
low neuronal ambient GABA with tonic chloride currents (Mody, 
2001; Wisden et al., 2002; Caraiscos et al., 2004; Mody and Pearce, 
2004). Therefore, amino acid substitution at this position of the 
ligand binding domain should increase the apparent GlyR agonist 
affi nity. Indeed, proline-to-leucine substitution by C-to-U editing 
of GLRA3 transcripts was shown to increase the apparent ago-
nist affi nity (Meier et al., 2005). Similarly, editing of GLRA2 tran-
scripts at the corresponding position (192) produces receptors with 
increased apparent agonist affi nity (Eichler et al., 2008).
To further emphasize the critical role of position 185/192 in 
determining apparent receptor agonist affi nity dose-response curves 
were obtained from HEK293 cells expressing GlyR α1185P or α1185L 
(Figure 1). The short GlyR α1 splice variant lacking insert SPMLNLFQ 
(Malosio et al., 1991) was used throughout. Again, compared with 
GlyR α1185P, the apparent affi nity of α1185L channels was increased 
several fold [EC
50(Glycine)
 (µM) α1185L: 17.7 ± 1.5 vs. α1185P: 85.3 ± 4.4, 
EC
50(Taurine)
 (µM) α1185L: 67.0 ± 6. 8 vs. α1185P: 378 ± 33, mean ± SD].
It should be noted here that the apparent affi nity of GlyRs does 
not seem to be infl uenced by RNA splicing because GlyR α1 with 
insertion (α1ins) (Malosio et al., 1991) exhibited similar current 
profi les (not shown). In addition, compared with α3K, the long 
splice variant of α3-GlyRs (α3L) (Nikolic et al., 1998) also had 
increased apparent glycine affi nity when RNA-edited (Figure 2).
Altogether, proline-to-leucine substitution at positions 192 (α2) 
and 185 (α1 and α3) confers high apparent agonist affi nities to GlyRs. 
On the contrary, GlyR apparent agonist affi nity is not  regulated by 
FIGURE 1 | Apparent agonist affi nities of GlyR α1185P and α1185L. 
Dose-response curves were obtained from transfected HEK293 cells. 
(A,C) Example traces of Cl− currents obtained at indicated agonist 
concentrations. At −70 mV holding potential, maximal current responses 
(α1185P, taurine: 3.3 ± 0.3 nA, glycine: 2.5 ± 0.3 nA; α1185L, taurine: 1.7 ± 0.3 nA, 
glycine: 1.6 ± 0.3 nA) were obtained with 2 mM glycine and 10 mM taurine. 
Taurine (B) and glycine (D) dose-response curves of HEK293 cells expressing 
GlyR α1185P or α1185L are shown. Taurine and glycine current amplitudes were 
normalized to maximal current amplitudes. Each data point (B,D) represents 
the average current amplitude of 13–21 sampled cells. Hill coeffi cients: α1185P, 
taurine: 1.06 ± 0.09, glycine: 1.88 ± 0.17; α1185L, taurine: 0.84 ± 0.07, glycine: 
1.08 ± 0.09. Values represent mean ± SD.
RNA splicing, except for GlyR α2 where changes in the apparent 
affi nity were observed upon RNA splicing in the region coding for 
the N-terminal domain (Miller et al., 2004; Eichler et al., 2008).
HOW RNA EDITING CAN CHANGE RECEPTOR-CHANNEL 
KINETICS, A PERSPECTIVE
RNA editing involves a single amino acid substitution in the 
N-terminal GlyR domain. The main consequence of RNA editing is 
an increase in the apparent affi nities (EC
50
) of GlyRs for glycine and 
taurine. RNA editing does not modify GlyR desensitization kinet-
ics (Meier et al., 2005), which is consistent with previous studies 
showing that receptor desensitization kinetics are mainly affected 
by change in amino acid sequences in the TM3-4 loop (Legendre, 
2001; Breitinger and Becker, 2002; Breitinger et al., 2002). A single 
amino acid substitution in the N-terminal GlyR domain at posi-
tions 192 (α2) or 185 (α1 and α3) could result in a change in the 
transduction process between agonist binding and channel gat-
ing, but it cannot be excluded at this stage that proline-to-leucine 
Frontiers in Molecular Neuroscience www.frontiersin.org November 2009 | Volume 2 | Article 23 | 3
Legendre et al. GlyR posttranscriptional processing
 substitution modifi es the conformation of the N-terminal domain 
and hence the access of the ligand to the binding pocket. Changes in 
EC
50
 values do therefore not necessarily imply changes in the affi n-
ity of the receptor for its agonist. Effectively, in the simplest case, 
the EC
50
 depends both on the agonist dissociation constant (Kd) 
and on the receptor-channel effi cacy (E), and EC
50
 = Kd/(1 + E) 
[for a more detailed explanation see (Colquhoun, 1998; Legendre, 
2001)]. Several models have been proposed to describe GlyR acti-
vation kinetics, e.g. the “reluctant gating model” (Legendre, 1998) 
and the “fl ip model” (Burzomato et al., 2004). The fl ip model was 
recently extended to nAChR (Lape et al., 2008), although it has 
partially been challenged recently (Mukhtasimova et al., 2009). 
In any case, these studies demonstrate that receptor channels can 
have intermediate conformational states between binding steps and 
opening states, which must be taken into account when interpreting 
changes in EC
50
. Accordingly, the best way to determine how GlyR 
RNA editing infl uences their apparent glycine affi nity will be to 
compare activation kinetics of regular and RNA-edited GlyRs at 
the single channel level, as was already done in case of the hyper-
ekplexia amino acid substitution α1K276E (Lewis et al., 1998), the 
hyperekplexia amino acid substitution α1Q266H (Moorhouse et al., 
1999) and the spasmodic amino acid substitution α1A52S (Plested 
et al., 2007). Nonetheless, the net outcome of proline-to-leucine 
substitution is a gain-of-function GlyR.
CONFORMATIONAL IMPLICATIONS OF GlyR RNA EDITING
The crystal structure of the acetylcholine binding protein (AChBP) 
was recently determined at high resolution (Celie et al., 2005). 
Because members of the LGIC superfamily have a common 
ancestor (Celie et al., 2005) we have used the AChBP structure as 
a model for the ligand binding domain of GlyR. At least from the 
point of view of intramolecular location of β-sheets a  projection 
of GlyR sequences on AChBP protein structure can be made 
(Grenningloh et al., 1987). According to these thoughts proline 
185/192 of GlyR α subunits is located directly at the beginning 
of β-sheet 9 (Figure 3, β9), a position that is close to the plasma 
membrane where these receptors enter the cytosol through trans-
membrane domain (TM) 1 (Figure 3, C-terminus). The glycine 
binding pocket (Figure 3) is formed by two distant amino acid 
groups (Legendre, 2001), namely GY (160 and 161, respectively) 
and KYT (200, 202 and 204, respectively). These two domains are 
separated by β-sheets 7 and 10, and prolines 185/192 are part of 
the β8/β9-fl anked connecting F-loop (Figure 3).
Further pursuing these considerations we have arguments that 
support a conformational role of proline-to-leucine substitution. 
First, leucine residues have bifurcated non-polar side chains that 
can mediate interaction with membrane lipids, while proline is 
frequently found in regions where the protein backbone has to 
make a sharp turn. In fact, increasing local hydrophobicity at posi-
tion 250 (located between TM1 and TM2 close to the intracellular 
side of the plasma membrane) was shown to impact on receptor 
apparent affi nity (Breitinger et al., 2001; Breitinger and Becker, 
2002). In this case however, increased hydrophobicity decreased 
apparent GlyR affi nity and favored rapid desensitization. Second, 
the disulfi de bridge that connects β-sheets 6’ and 7 (Figure 3) could 
serve as a hinge (Laube et al., 1993), potentially transmitting con-
formational rearrangement by proline-to-leucine substitution to 
the glycine binding pocket. Third, the glycine binding sequence 
KYT is located within the C-loop (Figure 3), which was shown 
FIGURE 2 | Apparent agonist affi nities of GlyR α3L185P and α3L185L. 
Dose-response curves were obtained from transfected HEK293 cells. 
(A) Example traces of Cl− currents obtained at indicated agonist 
concentrations. (B) Glycine dose-response curves of HEK293 cells expressing 
GlyR α3L185P or α3L185L are shown. Glycine current amplitudes were 
normalized to maximal current amplitudes. Each data point represents the 
average current amplitude of 13–21 sampled cells. At −70 mV holding 
potential, the apparent affi nities for glycine (EC50(Glycine) [µM]) were 70.9 ± 16.1 
(α3L185P) and 7.4 ± 0.9 (α3L185L). Hill coeffi cients were 0.87 ± 0.17 (α3L185P) and 
0.70 ± 0.06 (α3L185L). Thus, the long splice variant of RNA-edited GlyR α3L185L 
is a high affi nity receptor as well. Values represent mean ± SD.
FIGURE 3 | Tertiary structure of AChBP and projection of GlyR α subunit 
associated structural determinants. Positions of the glycine (yellow) binding 
pocket, formed by amino acids GY and KYT (C-loop), of the disulfi de bridge 
between β-sheets 6’ and 7 as well as of proline residues at positions 185 (α1 
and α3) and 192 (α2) are shown. N- and C-termini and the location of the 
chloride channel pore are indicated. β-sheets, α-helices and coils are color-
coded (green, red and black, respectively). GlyR sequence was projected on 
the structure view of AChBP downloaded from www.pdb.org. The position of 
β-sheets served as reference points.
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to undergo conformational change upon AChR agonist binding 
(Unwin et al., 2002), and fourth, F-loop dynamics are involved 
in benzodiazepine mediated GABA
A
R  activation (Padgett and 
Lummis, 2008). More recently, the F-loop was involved in sensing 
conformational rearrangements upon ligand docking (Pless and 
Lynch, 2009). Therefore, we put forward the idea that structural 
rearrangement by proline-to-leucine substitution will impact on 
the accessibility of GlyR agonists to the C-loop binding pocket.
GABA ACTIVATES RNA-EDITED GlyRs
Because proline-to-leucine substitution can cause structural rear-
rangement and therefore impact on accessibility of GlyR agonists 
to the C-loop binding pocket we have considered possible GABA 
responsiveness of RNA-edited GlyRs. Non-edited GlyRs can be acti-
vated by GABA at concentrations in the millimolar range (De Saint 
et al., 2001), which apparently precluded any physiological role for 
GABA on GlyRs. However, an elegant study recently demonstrated 
the opposite. Lu and colleagues (Lu et al., 2008) show that co-release 
of GABA and glycine accelerates glycinergic transmission by acting 
directly on GlyRs. This effect is explained by competition of GABA 
and glycine with the same binding site. The deactivation phase time 
constant of a synaptic event refl ects the duration of bursts of channel 
openings (Legendre, 2001). Since burst duration partly depends on 
the dissociation rate constant of the agonist, a weak partial agonist 
will evoke bursts of short duration, which will in turn result in a 
decrease in the deactivation time constant of the synaptic response. 
It is tempting to speculate that postsynaptic GlyRs facing GABAergic 
nerve endings as observed in some CNS area such as hippocam-
pus, and brain stem and spinal cord during development, could be 
activated by synaptic GABA release (Geiman et al., 2002; Levi et al., 
2004; Meier and Grantyn, 2004; Muller et al., 2006). However, the 
concentration of GABA, released into the synaptic clef, must be high 
enough (>1 mM) to activate GlyRs. This limitation can be overcome 
as GlyRs acquire a higher agonist affi nity if RNA-edited (Meier et al., 
2005; Eichler et al., 2008). As GABA is a week competitive partial 
agonist on GlyRs it is likely that an increase in the apparent affi nity 
for glycine will also result in an increase in the apparent affi nity for 
GABA. This is the case (Figure 4).
As shown in Figure 4 the threshold for GlyR activation by 
GABA is >0.3 mM in case of GlyR α3K185P, whereas it is close to 
0.1 mM for RNA-edited GlyR α3K185L. Interestingly, application of 
10 mM GABA (Figure 4B) on outside-out patches containing GlyR 
α3K185L evoked responses with amplitudes representing ∼80% of 
current amplitudes obtained with saturating glycine concentration 
(0.1 mM) (Meier et al., 2005). We did not test the effect of GABA 
concentrations above 10 mM, but according to the amplitude of 
GABA-evoked responses relative to current amplitudes obtained 
with 0.1 mM glycine, the apparent affi nity of GlyR α3K185L for 
GABA (EC
50
) is in the range of 2−3 mM (Figure 4B).
At GABAergic synapses the peak concentration of GABA mol-
ecules released per vesicle is likely to range from 0.5 to 1 mM 
(Jones and Westbrook, 1995). Accordingly, GlyR α3185L could be 
partially activated if located vis-à-vis GABAergic nerve endings. In 
fact, we have shown recently that GlyR α3K preferentially associ-
ates with GABAergic hippocampal nerve endings (Eichler et al., 
2009). However, it still remains to be shown that RNA-edited α3K 
behaves similarly.
A ROLE FOR α3-GlyRs AT GLUTAMATERGIC SYNAPSES?
In addition to these fi ndings, recent analysis of α3-GlyR distribu-
tion revealed an unexpected location of the long splice variant 
of these receptors (α3L) adjacent to glutamatergic nerve endings 
FIGURE 4 | Activation of GlyR α3K185P and GlyR α3K185L by GABA 
applications. (A1) Example traces of outside-out currents evoked by activation 
of GlyR α3K185P in response to the application of glycine (0.1 mM) and various 
concentrations of GABA (Vh = −50 mV; Filter 1 kHz). (A2) Example traces of 
outside-out currents evoked by activation of GlyR α3K185L in response to the 
application of glycine (0.1 mM) and various concentrations of GABA 
(Vh = −50 mV; Filter 1 kHz). (B) Concentration-response curves for GABA-evoked 
currents on outside-out patches containing GlyR α3K185P (?) or GlyR α3K185L (?). 
Measurements were performed on averaged traces. The amplitude of GABA-
evoked currents was normalized to the peak amplitude of the current evoked by 
the application of 0.1 mM glycine (relative current). Numbers above data points 
indicate the number of measurements per point (mean ± SD).
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in hippocampal principle cell layers in adult mice (Eichler et al., 
2009). It therefore is conceivable that activation of GlyRs can 
evoke local chloride currents at glutamatergic synapses, which will 
reduce the effi cacy of these synapses. However, these GlyRs must 
be activated at the level of glutamatergic postsynaptic domains. 
Presence of glycine transporter 1 at hippocampal glutamatergic 
synapses (Cubelos et al., 2005) together with the observation of 
postsynaptic glutamatergic responses with recurrent small strych-
nine-sensitive components (Müller et al., 2007) can support this 
hypothesis, particularly in case of RNA-edited receptors (Meier 
et al., 2005; Eichler et al., 2008). Again, it remains to be shown 
whether RNA editing impacts on the subcellular distribution of 
these receptors.
HIGH AFFINITY GlyR EFFECTIVELY INHIBITS NEURONAL 
ACTIVITY THROUGH SHUNT INHIBITION
It is now well established that GlyRs are highly mobile entities of 
the neuronal plasma membrane (Meier et al., 2001; Dahan et al., 
2003), which implies that receptors have a certain probability to 
be encountered at non-synaptic locations.
In the hippocampus, functional glycinergic synapses have not 
been described, and the majority of α3-GlyR immunoreactiv-
ity indeed is found at non-synaptic places (Eichler et al., 2009). 
Furthermore, it has recently been shown that glycine uptake can 
regulate hippocampal network activity via GlyR-mediated non-
synaptic tonic inhibition (Zhang et al., 2008), and the source of 
extracellular glycine was suggested to be glial cells (Zhang et al., 
2008). A continuous activation of non-synaptic receptors requires 
a suffi cient amount of extracellular glycine or taurine. However, 
in the central nervous system, the concentration of glycine is 
tightly regulated by glycine transporters (Gomeza et al., 2003), 
and the residual glycine concentration in the extracellular space 
is likely to be close to 0.1 µM in normal conditions (Roux and 
Supplisson, 2000).
Extracellular glycine can increase temporarily in case of sus-
tained presynaptic activity (Roux and Supplisson, 2000; Supplisson 
and Roux, 2002), as for example in the epileptic tissue where hyper-
synchronous high frequency network activity occurs (Fisher et al., 
1992; Bragin et al., 2007). Accordingly, this might have important 
functional consequences, because non-synaptic slightly desensitiz-
ing GlyRs could be continuously activated as a result of temporarily 
altered GlyT activity (e.g. reverse transport) or even due to gly-
cine spillover. Remarkably, the embryonic form of GlyRs, which is 
composed of fi ve α2 subunits and expressed before synaptogenesis 
displays functional properties adapted to non-synaptic release of 
the agonist (Mangin et al., 2003). Therefore, it can sustain a long 
lasting activation state when the extracellular glycine concentration 
increases above its activation threshold (Mangin et al., 2003).
Irrespective of the subunit, remarkable features of RNA-edited 
GlyRs are their high apparent affi nities for glycine (Meier et al., 2005; 
Eichler et al., 2008). Effectively, these receptors can be activated by 
very low glycine concentrations. In case of GlyR α3185L, 300 nM 
glycine already is suffi cient for receptor activation, which in turn 
results in the occurrence of single channel openings. Independently 
of the chloride equilibrium potential, the activation of several GlyR 
α3185L can evoke an inhibition of the neuronal activity. Effectively, 
the opening of several channels can lead to a decrease in the cell 
input resistance, which will reduce the propagation of synaptic 
events and of action potentials, resulting in an inhibitory shunting 
process (Eichler et al., 2008).
HIGH AFFINITY GlyRs ARE HARMFUL FOR HIPPOCAMPAL 
NEURONS WITH HIGH CHLORIDE EQUILIBRIUM POTENTIAL
Although GlyRs were reported to have anticonvulsant effects 
(Kirchner et al., 2003; Song et al., 2006) results obtained more 
recently (Eichler et al., 2008) point to a pathophysiological role of 
enhanced GlyR-mediated signaling, particularly in the context of 
high chloride equilibrium potential as is the case in TLE (Palma 
et al., 2006). Under these circumstances, neuron silencing triggers 
up-regulation of the ratio between glutamatergic and GABAergic 
nerve terminals and is associated with abnormal dendrite mor-
phology (Lohmann et al., 2005; Eichler et al., 2008), both of which 
phenomena are reminiscent of the TLE histopathology (Loup et al., 
2000; Stief et al., 2007). Most importantly, silenced hippocampal 
neurons were prone to die due to glutamate excitotoxicity, but 
amongst others could be rescued by expression of the potassium 
chloride cotransporter type 2 (KCC2) (Eichler et al., 2008). KCC2 
expression provides neurons with an effi cient chloride extrusion 
mechanism that decreases their chloride equilibrium potential (Lee 
et al., 2005). Although the mechanisms underlying this neuropro-
tective effect of KCC2 remained obscure our results support the 
previously postulated developmentally dichotomous effects of sin-
gle cell activity deprivation on neuron integrity within an otherwise 
active neuronal network (Tao and Poo, 2005).
Furthermore considering altered GLRA3 splicing in the hip-
pocampus of TLE patients, favouring association of α3-GlyRs 
with hippocampal GABAergic synapses, the net outcome of 
anomalous posttranscriptional GLRA3 processing is predicted 
to add to the pathophysiology of TLE. In a worst case scenario, 
provided that the chloride equilibrium potential is high enough 
(Rivera et al., 2004; Palma et al., 2006; Eichler et al., 2008), up-
regulation of RNA-edited α3K-GlyRs (associated preferentially 
with GABAergic synapses) accompanied by down-regulation of 
RNA-edited α3L-GlyRs (associated preferentially with glutamater-
gic synapses) could increase glycinergic signalling at depolarizing 
GABAergic synapses while reducing inhibitory effects on glutama-
tergic postsynaptic currents.
EXPERIMENTAL STRATEGIES FOR DETECTION OF RNA-EDITED 
GlyR PROTEIN
In any case, it is necessary to prove the existence of RNA-edited 
GlyR protein. However, this fi gured out to be rather diffi cult. 
Because of the position of leucine 185/192 at the interior of the 
channel pore close to the plasma membrane antibody accessibil-
ity is predicted to be low. Indeed, a potentially GlyR α3185L-spe-
cifi c antibody obtained by immunization of guinea pigs with 
peptide EGLTLLQFLLK (185L, underlined and bold) and cross-
 absorption against peptide EGLTLPQFLLK (185P, underlined 
and bold) was not able to visualize RNA-edited GlyR α3185L in 
transfected HEK293 (not shown). Even variation of fi xation pro-
tocols and reagents did not ameliorate cellular protein detection. 
Therefore, it will be necessary to isolate a particular single chan-
nel conductance specifi c to RNA-edited GlyRs or any other dif-
ferentiating factor in order to validate existence of these proteins 
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in neuronal tissue. It is conceivable to screen ligand databases for 
the presence of agonists or antagonists specifi c to RNA-edited 
GlyRs. So far, however, poor availability of reliable chloride indi-
cators applicable to living cells was a rather rate limiting step in 
identifi cation of novel ligands.
CONCLUSION
RNA-edited GlyRs may open avenues to medication of excit-
ability disorders (Eichler and Meier, 2008) because they could 
provide researchers and clinicians with a battery of new thera-
peutically relevant drugs, yet these enigmatic receptors still 
have to be captured at the protein level of investigation. In 
 particular, a possible cell-type specifi c hippocampal expression 
has to be determined.
SUPPORTING METHODS
WHOLE-CELL PATCH-CLAMP RECORDINGS
Whole-cell patch-clamp recordings of HEK293 cells were per-
formed 2–3 days after Ca2+-phosphate transfection with α1-GlyR 
constructs. For electrophysiological recordings, the growth medium 
was replaced with a bath solution containing (in mM): 145 NaCl, 
2.5 KCl, 20 HEPES, 10 glucose, 2 CaCl
2
, 1 MgCl
2
, adjusted to pH 7.3. 
All recordings were carried out at room temperature using patch-
clamp amplifi er EPC-9 (HEKA Elektronik, Lambrecht, Germany). 
Patch electrodes were fabricated from borosilicate glass capillar-
ies tubing using a P-97 puller (Sutter Instruments, Novato, CA, 
USA). The pipette solution contained (in mM): 4 NaCl, 130 KCl, 
5 EGTA, 10 HEPES, 10 glucose, 0.5 CaCl
2
, 4 MgCl
2
, adjusted to pH 
7.3. The pipette-to-bath DC resistance of patch electrodes ranged 
from 2–4 MOhm. Recordings were performed at a holding poten-
tial of −70 mV. Glycine or taurine was locally applied for 3 s via a 
 gravity-driven 5-channel superfusion system. An interval of at least 
60 s was left between successive agonist concentrations to allow for 
recovery from receptor desensitization. Different agonist concen-
trations were applied randomly. Electrophysiological signals were 
sampled at a rate of 5 kHz, fi ltered at 1 kHz and analyzed off-line 
using software TIDA 5.1 (HEKA Electronics, Lambrecht, Germany). 
To determine the EC
50
 value for agonists, peak currents obtained 
with different glycine or taurine concentrations were plotted and 
fi tted to the Hill equation using software Origin 7.0 (OriginLab, 
Northampton, USA).
OUTSIDE-OUT PATCH-CLAMP RECORDINGS
Outside-out patch-clamp recordings of HEK293 cells were per-
formed 2 days after Ca2+-phosphate transfection with α3K185P or 
α3K185L GlyR constructs. Cells were continuously perfused at room 
temperature (20–22°C) with bathing solution (2 ml/min) containing 
(in mM): NaCl 147, KCl 2.4, CaCl
2
 2, MgCl
2
 2, HEPES 10, glucose 10 
(pH 7.2, osmolarity 320 mOsm). Patch-clamp electrodes (5–10 MΩ) 
were pulled from thick-wall borosilicate glass (Harvard Apparatus, 
Kent, UK) using a Brown-Flaming puller (Sutter Instrument Co., 
Navato, USA). They were fi re-polished and fi lled with (in mM): 
CsCl 130, MgCl
2
 4, Na
2
ATP 4, EGTA 10, HEPES 10 (pH 7.2, osmo-
larity 290 mOsm). Currents were recorded using an Axopatch 1D 
amplifi er (Axon Instruments, Foster City, USA). Recordings were fi l-
tered at 10 kHz using an eight-pole bessel fi lter (Frequency Devices, 
Haverhill, USA), sampled at 50 kHz and stored on a PC computer 
using pClamp software 10.1. (Axon Instruments, Foster City, USA). 
The membrane potential was held at −50 mV throughout the experi-
ment. Outside-out single-channel currents were evoked using a fast-
fl ow operating system (Legendre, 1998). Control and drug solution 
were gravity-fed into two channels of a thin-wall glass theta tube 
(2-mm outer diameter; Hilgenberg, Malsfeld, Germany) pulled and 
broken to obtain a 200-µm tip diameter. The outside-out patch was 
positioned 100 µm away from the glass theta tube, one lumen of the 
application pipette was connected to reservoirs fi lled with solutions 
containing glycine or GABA. The solution exchange was performed 
by rapidly moving the solution interface across the tip of the patch 
pipette, using a piezo-electric translator (model P245.30, Physik 
Instrument, Waldbronn, Germany). Concentration steps of glycine 
or GABA were applied with an interval of ≥10 s. Exchange time 
solution (<100 µs) was determined before each set of experiments 
by monitoring the change in the liquid junction potential evoked 
by the application of a 10%-diluted control solution to the open 
tip of the patch pipette.
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